Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...